+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type, Indication Type, Technology Type, Region, and Segment Forecasts, 2026-2033- Product Image
Cancer Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type, Indication Type, Technology Type, Region, and Segment Forecasts, 2026-2033- Product Image
New

Cancer Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type, Indication Type, Technology Type, Region, and Segment Forecasts, 2026-2033

  • PDF Icon

    Report

  • 150 Pages
  • January 2026
  • Region: Global
  • Grand View Research
  • ID: 5853863
REQUEST CUSTOMIZATION
Description Jump to:
The global cancer vaccine market size was estimated at USD 9.93 billion in 2025 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. This growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy-based treatments, and rapid advancements in vaccine technologies such as mRNA, dendritic cell platforms, and personalized neoantigen vaccines.

The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option. Advances in vaccine technology, such as mRNA and DNA platforms, have significantly improved the ability to design vaccines that teach the immune system to recognize cancer-specific antigens and destroy tumor cells more effectively than traditional therapies.

Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited. For instance, in January 2026, Moderna and Merck reported that their personalized cancer vaccine used with Keytruda showed a sustained reduction in risk of recurrence or death in high-risk melanoma patients during long-term follow-up, reinforcing confidence in vaccine approaches and driving further clinical development and funding.

Another major growth factor in the Cancer Vaccine industry is the rapid pace of scientific innovation improving the precision and effectiveness of vaccine candidates. New techniques in antigen identification, neoantigen targeting, and computational biology have enabled vaccines to be tailored to the unique genetic profile of individual tumors, which is critical for triggering a robust immune response. The expanding pipeline of clinical trials demonstrates increasing confidence among researchers and investors that Cancer Vaccine can deliver meaningful benefits across multiple cancer types, including those historically difficult to treat.

For instance, in July 2025, Scientists at the University of Florida developed an experimental mRNA vaccine that triggered a strong anticancer immune response against tumors in preclinical models, highlighting both the promise of next-generation vaccines and the technological momentum supporting market growth.

Market growth is also propelled by supportive policy environments, increasing public awareness of cancer prevention and early detection, and the integration of novel diagnostic tools that work in tandem with vaccine strategies. Governments and health agencies have intensified funding for immunotherapy research, and collaborations between biotech firms and research institutions are becoming more common, which accelerates product development and regulatory approval pathways.

Moreover, the success of vaccine platforms during the COVID-19 pandemic has reinforced confidence in mRNA technology for other diseases, including cancer, leading to greater investment and quicker translation of research into clinical applications. For instance, in September 2025, Russia announced that its new cancer vaccine Enteromix, developed using advanced mRNA technology, was ready for clinical use and would be provided free to patients following regulatory approval, illustrating both the technological progress and policy support driving market expansion.

Global Cancer Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global Cancer Vaccine market report based on vaccine type, indication type, technology type, and region:

Vaccine Type Outlook (Revenue, USD Million, 2021-2033)

  • Preventive Cancer Vaccine
  • Therapeutic Cancer Vaccine
  • Others

Indication Type Outlook (Revenue, USD Million, 2021-2033)

  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Other

Technology Type Outlook (Revenue, USD Million, 2021-2033)

  • Recombinant Cancer Vaccine
  • Whole-cell Cancer Vaccine
  • Viral Vector and DNA Cancer Vaccine
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vaccine Type
1.2.2. Indication Type
1.2.3. Technology Type
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Cancer Vaccine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Cancer Vaccine Market: Vaccine Type Business Analysis
4.1. Vaccine Type Market Share, 2025 & 2033
4.2. Vaccine Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
4.4. Preventive Cancer Vaccine
4.4.1. Preventive Cancer Vaccine Market, 2021-2033 (USD Million)
4.5. Therapeutic Cancer Vaccine
4.5.1. Therapeutic Cancer Vaccine Market, 2021-2033 (USD Million)
4.6. Others
4.6.1. Others Market, 2021-2033 (USD Million)
Chapter 5. Cancer Vaccine Market: Indication Type Business Analysis
5.1. Indication Type Market Share, 2025 & 2033
5.2. Indication Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication Type, 2021 to 2033 (USD Million)
5.4. Prostate Cancer
5.4.1. Prostate Cancer Market, 2021-2033 (USD Million)
5.5. Bladder Cancer
5.5.1. Bladder Cancer Market, 2021-2033 (USD Million)
5.6. Melanoma
5.6.1. Melanoma Market, 2021-2033 (USD Million)
5.7. Cervical Cancer
5.7.1. Cervical Cancer Market, 2021-2033 (USD Million)
5.8. Other
5.8.1. Other Market, 2021-2033 (USD Million)
Chapter 6. Cancer Vaccine Market: Technology Type Business Analysis
6.1. Technology Type Market Share, 2025 & 2033
6.2. Technology Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by technology type, 2021 to 2033 (USD Million)
6.4. Recombinant Cancer Vaccine
6.4.1. Recombinant Cancer Vaccine Market, 2021-2033 (USD Million)
6.5. Whole-cell Cancer Vaccine
6.5.1. Whole-cell Cancer Vaccine Market, 2021-2033 (USD Million)
6.6. Viral Vector and DNA Cancer Vaccine
6.6.1. Viral Vector and DNA Cancer Vaccine Market, 2021-2033 (USD Million)
6.7. Other Technologies
6.7.1. Other Technologies Market, 2021-2033 (USD Million)
Chapter 7. Cancer Vaccine Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Cancer Vaccine Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Technology Type Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Technology Type Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Technology Type Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Technology Type Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Technology Type Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Technology Type Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Technology Type Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Technology Type Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Technology Type Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Technology Type Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Technology Type Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Technology Type Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Technology Type Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Technology Type Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Technology Type Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Technology Type Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Technology Type Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Technology Type Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Technology Type Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Technology Type Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Technology Type Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Technology Type Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Technology Type Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Cancer Vaccine Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Merck & Co., Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. GSK plc
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Dendreon Pharmaceuticals LLC.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Dynavax Technologies.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Ferring B.V.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Amgen, Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Moderna, Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Sanofi
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. AstraZeneca
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Bristol-Myers Squibb Company
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Cancer Vaccine market, by region, 2021-2033 (USD Million)
Table 4 Global Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 5 Global Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 6 Global Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 7 North America Cancer Vaccine market, by country, 2021-2033 (USD Million)
Table 8 North America Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 9 North America Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 10 North America Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 11 U.S. Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 12 U.S. Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 13 U.S. Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 14 Canada Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 15 Canada Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 16 Canada Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 17 Mexico Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 18 Mexico Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 19 Mexico Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 20 Europe Cancer Vaccine market, by country, 2021-2033 (USD Million)
Table 21 Europe Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 22 Europe Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 23 Europe Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 24 UK Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 25 UK Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 26 UK Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 27 Germany Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 28 Germany Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 29 Germany Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 30 France Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 31 France Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 32 France Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 33 Italy Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 34 Italy Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 35 Italy Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 36 Spain Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 37 Spain Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 38 Spain Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 39 Norway Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 40 Norway Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 41 Norway Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 42 Denmark Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 43 Denmark Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 44 Denmark Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 45 Sweden Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 46 Sweden Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 47 Sweden Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 48 Asia Pacific Cancer Vaccine market, by country, 2021-2033 (USD Million)
Table 49 Asia Pacific Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 50 Asia Pacific Cancer Vaccine market, by indication type, 2021-2033 (USD
Table 51 Asia Pacific Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 52 Japan Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 53 Japan Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 54 Japan Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 55 China Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 56 China Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 57 China Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 58 India Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 59 India Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 60 India Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 61 Australia Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 62 Australia Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 63 Australia Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 64 South Korea Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 65 South Korea Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 66 South Korea Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 67 Thailand Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 68 Thailand Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 69 Thailand Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 70 Latin America Cancer Vaccine market, by country, 2021-2033 (USD Million)
Table 71 Latin America Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 72 Latin America Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 73 Latin America Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 74 Brazil Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 75 Brazil Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 76 Brazil Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 77 Argentina Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 78 Argentina Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 79 Argentina Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 80 Middle East & Africa Cancer Vaccine market, by country, 2021-2033 (USD Million)
Table 81 Middle East & Africa Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 82 Middle East & Africa Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 83 Middle East & Africa Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 84 South Africa Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 85 South Africa Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 86 South Africa Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 87 Saudi Arabia Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 88 Saudi Arabia Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 89 Saudi Arabia Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 90 UAE Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 91 UAE Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 92 UAE Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
Table 93 Kuwait Cancer Vaccine market, by vaccine type, 2021-2033 (USD Million)
Table 94 Kuwait Cancer Vaccine market, by indication type, 2021-2033 (USD Million)
Table 95 Kuwait Cancer Vaccine market, by technology type, 2021-2033 (USD Million)
List of Figures
Figure 1 Cancer Vaccine market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Competitive landscape
Figure 10 Cancer Vaccine market dynamics
Figure 11 Cancer Vaccine market: Porter’s five forces analysis
Figure 12 Cancer Vaccine market: PESTLE analysis
Figure 13 Vaccine Type market, 2021-2033 (USD Million)
Figure 14 Preventive Cancer Vaccine market, 2021-2033 (USD Million)
Figure 15 Therapeutic Cancer Vaccine market, 2021-2033 (USD Million)
Figure 16 Others market, 2021-2033 (USD Million)
Figure 17 Indication Type market, 2021-2033 (USD Million)
Figure 18 Prostate Cancer market, 2021-2033 (USD Million)
Figure 19 Bladder Cancer market, 2021-2033 (USD Million)
Figure 20 Melanoma market, 2021-2033 (USD Million)
Figure 21 Cervical Cancer market, 2021-2033 (USD Million)
Figure 22 Other market, 2021-2033 (USD Million)
Figure 23 Technology Type market, 2021-2033 (USD Million)
Figure 24 Recombinant Cancer Vaccine market, 2021-2033 (USD Million)
Figure 25 Whole-cell Cancer Vaccine market, 2021-2033 (USD Million)
Figure 26 Viral Vector and DNA Cancer Vaccine market, 2021-2033 (USD Million)
Figure 27 Other Technologies market, 2021-2033 (USD Million)
Figure 28 Cancer Vaccine market revenue, by region
Figure 29 Regional marketplace: Key takeaways
Figure 30 North America Cancer Vaccine market, 2021-2033 (USD Million)
Figure 31 U.S. country dynamics
Figure 32 U.S. Cancer Vaccine market, 2021-2033 (USD Million)
Figure 33 Canada country dynamics
Figure 34 Canada Cancer Vaccine market, 2021-2033 (USD Million)
Figure 35 Mexico country dynamics
Figure 36 Mexico Cancer Vaccine market, 2021-2033 (USD Million)
Figure 37 Europe Cancer Vaccine market, 2021-2033 (USD Million)
Figure 38 UK country dynamics
Figure 39 UK Cancer Vaccine market, 2021-2033 (USD Million)
Figure 40 Germany country dynamics
Figure 41 Germany Cancer Vaccine market, 2021-2033 (USD Million)
Figure 42 France country dynamics
Figure 43 France Cancer Vaccine market, 2021-2033 (USD Million)
Figure 44 Italy country dynamics
Figure 45 Italy Cancer Vaccine market, 2021-2033 (USD Million)
Figure 46 Spain country dynamics
Figure 47 Spain Cancer Vaccine market, 2021-2033 (USD Million)
Figure 48 Norway country dynamics
Figure 49 Norway Cancer Vaccine market, 2021-2033 (USD Million)
Figure 50 Sweden country dynamics
Figure 51 Sweden Cancer Vaccine market, 2021-2033 (USD Million)
Figure 52 Denmark country dynamics
Figure 53 Denmark Cancer Vaccine market, 2021-2033 (USD Million)
Figure 54 Asia Pacific Cancer Vaccine market, 2021-2033 (USD Million)
Figure 55 Japan country dynamics
Figure 56 Japan Cancer Vaccine market, 2021-2033 (USD Million)
Figure 57 China country dynamics
Figure 58 China Cancer Vaccine market, 2021-2033 (USD Million)
Figure 59 India country dynamics
Figure 60 India Cancer Vaccine market, 2021-2033 (USD Million)
Figure 61 Australia country dynamics
Figure 62 Australia Cancer Vaccine market, 2021-2033 (USD Million)
Figure 63 South Korea country dynamics
Figure 64 South Korea Cancer Vaccine market, 2021-2033 (USD Million)
Figure 65 Thailand country dynamics
Figure 66 Thailand Cancer Vaccine market, 2021-2033 (USD Million)
Figure 67 Latin America Cancer Vaccine market, 2021-2033 (USD Million)
Figure 68 Brazil country dynamics
Figure 69 Brazil Cancer Vaccine market, 2021-2033 (USD Million)
Figure 70 Argentina country dynamics
Figure 71 Argentina Cancer Vaccine market, 2021-2033 (USD Million)
Figure 72 MEA Cancer Vaccine market, 2021-2033 (USD Million)
Figure 73 South Africa country dynamics
Figure 74 South Africa Cancer Vaccine market, 2021-2033 (USD Million)
Figure 75 Saudi Arabia country dynamics
Figure 76 Saudi Arabia Cancer Vaccine market, 2021-2033 (USD Million)
Figure 77 UAE country dynamics
Figure 78 UAE Cancer Vaccine market, 2021-2033 (USD Million)
Figure 79 Kuwait country dynamics
Figure 80 Kuwait Cancer Vaccine market, 2021-2033 (USD Million)
Figure 81 Company categorization
Figure 82 Company market position analysis
Figure 83 Strategic framework

Companies Mentioned

The leading players profiled in this Cancer Vaccine market report include:
  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Ferring B.V.
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi
  • AstraZeneca
  • Bristol-Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages150
PublishedJanuary 2026
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 9.93 Billion
Forecasted Market Value ( USD ) by 2033 $ 23.31 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032 - Product Image

Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032

  • Report
  • 263 Pages
  • Global
From
US cancer vaccine industry outlook to 2028 - Product Image

US cancer vaccine industry outlook to 2028

  • Report
  • 85 Pages
  • United States
From
Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence - Product Image

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence

  • Directory
  • Global
From
Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2025-2033 - Product Image

Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and Forecast (2021-2031) - Product Image

Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and Forecast (2021-2031)

  • Report
  • 203 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.